BioGend Therapeutics Co (ROCO:6733) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6733 BioGend Therapeutics Co Ltd ROCO:6733
73 GF Score
Price NT$25.35
GF Value NT$70.22
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is BioGend Therapeutics Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

BioGend Therapeutics Co Valuation Rank Related Terms

ROCO:6733
73GF Score
BioGend Therapeutics Co Ltd ROCO:6733
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?

Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued. The current stock price of NT$25.35 is trading 63.9% below its estimated GF Value™ of NT$70.22. GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.

Key valuation signals for ROCO:6733:

  • Valuation Rank:
  • GF Value™: NT$70.22 vs. price of NT$25.35 (63.9% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioGend Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 115
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score

Get the complete analysis for ROCO:6733

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$25.35
Price
NT$70.22
GF Value